• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发性转移性宫颈癌的系统治疗进展。

Advances in systemic treatment for recurrent metastatic cervical cancer.

机构信息

School of Medicine, Kunming University of Science and Technology, Kunming, Yunnan, China.

Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China.

出版信息

Br J Hosp Med (Lond). 2024 Oct 30;85(10):1-10. doi: 10.12968/hmed.2024.0279. Epub 2024 Oct 14.

DOI:10.12968/hmed.2024.0279
PMID:39475025
Abstract

Cervical cancer remains a leading cause of cancer-related mortality among women worldwide, particularly in underdeveloped nations. Despite advances in standard therapies, patients with recurrent metastatic cervical cancer face a poor prognosis and limited treatment options. This study aims to evaluate the efficacy and safety of emerging therapeutic approaches in managing this challenging condition, including immunotherapy, targeted medicines, and chemotherapy. Our review of recent literature and clinical trials highlights the significant progress made in the systematic treatment of metastatic cervical cancer. While each treatment modality has its strengths and limitations, the collective data suggest a trend towards improved patient outcomes with the adoption of these novel therapies. However, the heterogeneity of patient responses underscores the need for personalised treatment strategies. In conclusion, improvements in medical technology and the adoption of tailored treatment approaches have led to promising advancements in the management of recurrent metastatic cervical cancer. To further enhance patient care, there is an urgent need for more extensive clinical trial data and the development of more efficient personalised treatment plans. This study aims to contribute to this effort by comprehensively analysing current therapeutic strategies and identifying areas for future research.

摘要

宫颈癌仍然是全世界女性癌症相关死亡的主要原因,特别是在欠发达国家。尽管标准治疗方法有所进展,但患有复发性转移性宫颈癌的患者预后较差,治疗选择有限。本研究旨在评估新兴治疗方法在治疗这种具有挑战性疾病方面的疗效和安全性,包括免疫疗法、靶向药物和化疗。我们对最近的文献和临床试验进行了综述,强调了在转移性宫颈癌的系统治疗方面取得的重大进展。虽然每种治疗方法都有其优势和局限性,但综合数据表明,随着这些新疗法的采用,患者的预后有改善的趋势。然而,患者反应的异质性突出表明需要制定个性化的治疗策略。总之,医疗技术的进步和个性化治疗方法的采用为复发性转移性宫颈癌的治疗带来了有希望的进展。为了进一步提高患者的护理水平,迫切需要更广泛的临床试验数据和更有效的个性化治疗计划。本研究旨在通过全面分析当前的治疗策略并确定未来的研究领域来为此做出贡献。

相似文献

1
Advances in systemic treatment for recurrent metastatic cervical cancer.复发性转移性宫颈癌的系统治疗进展。
Br J Hosp Med (Lond). 2024 Oct 30;85(10):1-10. doi: 10.12968/hmed.2024.0279. Epub 2024 Oct 14.
2
The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.晚期宫颈癌一线治疗后全身治疗的影响
Clin Oncol (R Coll Radiol). 2017 Mar;29(3):153-160. doi: 10.1016/j.clon.2016.10.002. Epub 2016 Nov 9.
3
Chemotherapy for recurrent and metastatic cervical cancer.复发性和转移性宫颈癌的化疗
Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S67-71. doi: 10.1016/j.ygyno.2008.04.024. Epub 2008 Jun 3.
4
The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.提高晚期和转移性宫颈癌治疗水平的必要性,联合化疗-免疫治疗的基本原理。
Anticancer Agents Med Chem. 2014 Feb;14(2):190-203. doi: 10.2174/18715206113136660372.
5
Treatment of metastatic cervical cancer: future directions involving targeted agents.转移性宫颈癌的治疗:靶向药物的未来方向。
Crit Rev Oncol Hematol. 2013 Mar;85(3):303-14. doi: 10.1016/j.critrevonc.2012.07.006. Epub 2012 Aug 9.
6
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.复发性宫颈癌的药物治疗:文献更新。
Expert Opin Pharmacother. 2024 Jan-Apr;25(1):55-65. doi: 10.1080/14656566.2023.2298329. Epub 2024 Feb 1.
7
Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer.宫颈癌治疗的合理设计:针对复发性、转移性或难治性宫颈癌的基于细胞和非细胞的策略。
Expert Opin Drug Discov. 2018 May;13(5):445-457. doi: 10.1080/17460441.2018.1443074. Epub 2018 Feb 26.
8
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.一线铂类方案治疗后复发/晚期宫颈癌患者的管理:我们目前的状况如何?文献综述
Crit Rev Oncol Hematol. 2016 Dec;108:164-174. doi: 10.1016/j.critrevonc.2016.11.006. Epub 2016 Nov 15.
9
Immunotherapy and targeted therapy for cervical cancer: an update.宫颈癌的免疫治疗和靶向治疗:最新进展
Expert Rev Anticancer Ther. 2016;16(1):83-98. doi: 10.1586/14737140.2016.1121108. Epub 2015 Dec 7.
10
Chemotherapy for metastatic and recurrent cervical cancer.转移性和复发性宫颈癌的化疗
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD006469. doi: 10.1002/14651858.CD006469.pub2.

引用本文的文献

1
Single-cell transcriptomic analyses reveal heterogeneity and key subsets associated with survival and response to PD-1 blockade in cervical squamous cell carcinoma.单细胞转录组分析揭示了宫颈鳞状细胞癌中与生存及对PD-1阻断反应相关的异质性和关键亚群。
Cancer Cell Int. 2025 Mar 13;25(1):90. doi: 10.1186/s12935-025-03725-x.
2
Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials.妇科癌症中的免疫检查点抑制剂:关于改变实践的试验的叙述性综述
Immunotherapy. 2025 Jan;17(1):57-66. doi: 10.1080/1750743X.2025.2460964. Epub 2025 Feb 1.